Bridgewater Associates LP Purchases 39,216 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bridgewater Associates LP boosted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 55.7% in the 4th quarter, HoldingsChannel reports. The firm owned 109,678 shares of the medical equipment provider’s stock after acquiring an additional 39,216 shares during the period. Bridgewater Associates LP’s holdings in Lantheus were worth $9,812,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Portolan Capital Management LLC raised its stake in Lantheus by 21.1% in the 4th quarter. Portolan Capital Management LLC now owns 812,630 shares of the medical equipment provider’s stock valued at $72,698,000 after acquiring an additional 141,749 shares during the period. CreativeOne Wealth LLC raised its position in shares of Lantheus by 38.9% in the fourth quarter. CreativeOne Wealth LLC now owns 7,175 shares of the medical equipment provider’s stock valued at $642,000 after purchasing an additional 2,008 shares during the period. Synovus Financial Corp lifted its stake in shares of Lantheus by 13.4% during the 4th quarter. Synovus Financial Corp now owns 25,639 shares of the medical equipment provider’s stock worth $2,294,000 after buying an additional 3,038 shares during the last quarter. Granite Investment Partners LLC boosted its holdings in shares of Lantheus by 3.2% during the 4th quarter. Granite Investment Partners LLC now owns 51,149 shares of the medical equipment provider’s stock worth $4,576,000 after buying an additional 1,579 shares during the period. Finally, Townsquare Capital LLC acquired a new position in Lantheus in the 4th quarter valued at about $1,108,000. Institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LNTH. Truist Financial boosted their price objective on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. B. Riley lowered their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Finally, The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average price target of $129.43.

Lantheus Stock Performance

LNTH opened at $100.52 on Thursday. Lantheus Holdings, Inc. has a 52-week low of $61.46 and a 52-week high of $126.89. The firm has a market cap of $6.88 billion, a P/E ratio of 16.73 and a beta of 0.20. The business’s fifty day moving average is $94.71 and its 200-day moving average is $95.61.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.